Shares of NeoGenomics Inc. (NASDAQ:NEO) have received an average recommendation of “Buy” from the nine research firms that are presently covering the firm. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.67.

Several research firms recently commented on NEO. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 2nd. Axiom Securities restated a “sell” rating on shares of NeoGenomics in a research report on Wednesday, November 16th. First Analysis assumed coverage on NeoGenomics in a research report on Monday, October 3rd. They issued an “overweight” rating and a $11.00 target price on the stock. Raymond James Financial Inc. assumed coverage on NeoGenomics in a research note on Thursday, September 8th. They set an “outperform” rating and a $10.00 price target for the company. Finally, BTIG Research raised NeoGenomics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, October 27th.

NeoGenomics (NASDAQ:NEO) opened at 9.41 on Tuesday. The firm’s market capitalization is $738.80 million. The company has a 50-day moving average price of $8.16 and a 200 day moving average price of $8.35. NeoGenomics has a 1-year low of $5.49 and a 1-year high of $9.54.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 26th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.56% and a negative net margin of 3.10%. The firm had revenue of $60.76 million for the quarter, compared to analysts’ expectations of $61 million. During the same period last year, the firm earned $0.01 EPS. The firm’s revenue was up 141.8% compared to the same quarter last year. Equities analysts anticipate that NeoGenomics will post $0.14 earnings per share for the current year.

In other news, insider Maher Albitar sold 105,300 shares of the firm’s stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $8.20, for a total transaction of $863,460.00. Following the completion of the sale, the insider now directly owns 105,300 shares of the company’s stock, valued at approximately $863,460. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 12.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System raised its stake in NeoGenomics by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,810 shares of the company’s stock valued at $143,000 after buying an additional 190 shares in the last quarter. California Public Employees Retirement System raised its stake in NeoGenomics by 0.7% in the second quarter. California Public Employees Retirement System now owns 87,100 shares of the company’s stock valued at $700,000 after buying an additional 600 shares in the last quarter. California State Teachers Retirement System raised its stake in NeoGenomics by 0.7% in the third quarter. California State Teachers Retirement System now owns 112,330 shares of the company’s stock valued at $923,000 after buying an additional 800 shares in the last quarter. Nationwide Fund Advisors raised its stake in NeoGenomics by 2.9% in the second quarter. Nationwide Fund Advisors now owns 35,329 shares of the company’s stock valued at $284,000 after buying an additional 998 shares in the last quarter. Finally, ClariVest Asset Management LLC raised its stake in NeoGenomics by 1.4% in the third quarter. ClariVest Asset Management LLC now owns 81,300 shares of the company’s stock valued at $668,000 after buying an additional 1,100 shares in the last quarter. 77.88% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “NeoGenomics Inc. (NEO) Receives $10.67 Consensus Target Price from Analysts” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/25/neogenomics-inc-neo-receives-10-67-consensus-target-price-from-analysts.html.

NeoGenomics Company Profile

5 Day Chart for NASDAQ:NEO

Receive News & Stock Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related stocks with our FREE daily email newsletter.